KFAS
UTHR icon

Keating Financial Advisory Services’s United Therapeutics UTHR Stock Holding History

Keating Financial Advisory Services’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.7K Buy
149
+15
+11% +$8.45K 0.01% 560
2026
Q1 		$79.5K Buy
134
+6
+5% +$2.99K 0.01% 514
2025
Q4 		$62.4K Buy
+128
New +$59.6K 0.01% 607

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Keating Financial Advisory Services's UTHR Position: Q2 2026 in Review

Keating Financial Advisory Services increased its United Therapeutics (UTHR) stake by 11% in Q2 2026, buying an estimated $8.45K and bringing the position to 149 shares worth $80.7K. The position accounts for 0.01% of the portfolio, ranked #560.

Keating Financial Advisory Services first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Keating Financial Advisory Services held 149 shares of United Therapeutics worth $80.7K as of Q2 2026.
  • Keating Financial Advisory Services bought 15 United Therapeutics shares in Q2 2026, an estimated $8.45K.
  • United Therapeutics made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #560 holding.
  • Keating Financial Advisory Services first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.